Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
53 studies found for:    Open Studies | "Hemorrhagic Fevers, Viral"
Show Display Options
Rank Status Study
21 Recruiting Ketotifen as a Treatment for Vascular Leakage During Dengue Fever
Conditions: Dengue Fever;   Pleural Effusion
Interventions: Drug: Ketotifen;   Drug: Placebo
22 Recruiting Pilot Survey of Dengue Fever in Solomon Islands
Condition: Arbovirus Infections
Intervention:
23 Recruiting Cohort of Patients Infected by an Arbovirus
Conditions: Fever;   Dengue;   Chikungunya;   Zika Virus
Interventions: Other: biological sample collection;   Other: quality of life questionnaire EuroQol®;   Other: Health Assessment Questionnaire - MDHAQ and RAPID3
24 Recruiting Zika Virus and Related Arbovirus Infections in Deferred Blood Donors (ZVADD)
Conditions: Zika Virus;   Dengue Virus;   Chikungunya Virus Infections
Intervention:
25 Not yet recruiting Evaluating the Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TetraVax-DV) TV005 in Flavivirus-Naive Adults 50 to 70 Years of Age
Condition: Dengue
Interventions: Biological: TetraVax-DV TV005;   Biological: Placebo
26 Recruiting Evaluating the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With rDEN3Δ30
Condition: Dengue
Interventions: Biological: TetraVax-DV-TV005;   Biological: rDEN3Δ30;   Biological: Placebo
27 Recruiting Safety of Paracetamol as Antipyretic in Treatment of Dengue Infection in Adults
Conditions: Dengue;   Transaminitis
Interventions: Drug: Paracetamol;   Drug: Placebo
28 Recruiting This Study Will Describe the Burden of DENgue Fever Virus (DENV) Illness Among Household Members Aged 6 Months to 50 Years of Selected Communities in Latin America and Southeast Asia
Condition: Dengue
Intervention: Procedure: Blood sample collection
29 Recruiting Safety and Immunogenicity of the Dengue Virus Vaccine TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh
Condition: Dengue
Interventions: Biological: TV005 vaccine;   Biological: Placebo
30 Recruiting The Use of Biomarkers in Predicting Dengue Outcome
Condition: Dengue
Intervention:
31 Recruiting A Cohort Study to Determine the Incidence of Dengue Fever and to Build Capacity for Dengue Vaccine Trials in Dengue-endemic Regions of South Asia
Condition: Dengue
Intervention: Procedure: Blood sample collection
32 Recruiting Diagnosing Dengue: Evaluating the Utility of Oral Fluid for Dengue Diagnosis
Condition: Dengue
Intervention: Device: SaniSal Oral Fluid Collector
33 Recruiting Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2
Condition: Dengue
Interventions: Biological: Recombinant live attenuated trivalent dengue vaccine;   Biological: Placebo;   Biological: rDEN2Δ30-7169 vaccine
34 Recruiting Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant and Placebo in Healthy US Adults
Condition: Dengue
Intervention: Biological: TDENV-PIV with AS03B adjuvant. Placebo: 0.9% Sodium Chloride Solution.
35 Recruiting Phase III Trial to Evaluate Efficacy and Safety of a Tetravalent Dengue Vaccine
Condition: Dengue
Interventions: Biological: Dengue 1,2,3,4 (attenuated) vaccine;   Other: Placebo
36 Recruiting Evaluating the Clinical and Immune Response to Two Dengue Virus Vaccines in Healthy Adults
Condition: Dengue
Interventions: Biological: rDEN1Δ30;   Biological: Placebo;   Biological: rDEN2Δ30-7169
37 Recruiting Yellow Fever Vaccination Under Low Dose Methotrexate Therapy
Conditions: Rheumatic;   Dermatologic Disorders
Intervention: Biological: Yellow Fever Vaccination
38 Recruiting Evaluating the Safety of and Immune Response to a Dengue Vaccine (TV003) in Healthy Adults, Adolescents, and Children in Thailand
Condition: Dengue
Interventions: Biological: TV003;   Biological: Placebo for TV003
39 Recruiting TDENV PIV and LAV Dengue Prime-boost Strategy
Condition: Dengue
Interventions: Biological: TDENV-LAV;   Biological: TDENV-PIV 4 µg + alum adjuvant
40 Recruiting Efficacy and Safety of Ivermectin Against Dengue Infection
Condition: Dengue Fever
Interventions: Drug: 2 days Ivermectin;   Drug: 3 days Ivermectin;   Drug: Placebo

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-53) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.